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In the human endocrine system many protein hormones including urotensin, glucagon, obestatin, 
bombesin and secretin, among others, are supplied from amyloidal secretory granules. These granules 
form part of the so called functional amyloids, which within the whole aggregome appear to be more 
abundant than formerly believed. Bacterial inclusion bodies (IBs) are non-toxic, nanostructured 
functional amyloids whose biological fabrication can be tailored to render materials with defined 
biophysical properties. Since under physiological conditions they steadily release their building block 
protein in a soluble and functional form, IBs are considered as mimetics of endocrine secretory granules. 
We have explored here if the in vivo implantation of functional IBs in a given tissue would represent a 
stable local source of functional protein. Upon intratumoral injection of bacterial IBs formed by a potent 
protein ligand of CXCR4 we have observed high stability and prevalence of the material in absence of 
toxicity, accompanied by apoptosis of CXCR4+ cells and tumor ablation. Then, the local immobilization 
of bacterial amyloids formed by therapeutic proteins in tumors or other tissues might represent a 
promising strategy for a sustained local delivery of protein drugs by mimicking the functional amyloidal 
architecture of the mammals’ endocrine system.
As gene therapy is not yet of routine application1, deficiencies in endogenous proteins must be treated by the 
administration of externally fabricated proteins for protein replacement or as effective drugs2,3, including anti-
bodies, hormones or enzymes that exhibit a desired effect based on signalling, receptor blocking or substrate pro-
cessing4. These drugs are delivered by systemic administration, but adverse immune reactions and the high cost 
of treatments linked to the high doses required pose severe obstacles to this common approach. These constraints 
are exemplified by the treatment of lysosomal disorders, such as Fabry disease. In the treatment of this condition, 
1 mg/kg (Fabrazyme® ) or 0.2 mg/kg (Replagal® ) of protein are administered every two weeks to the patient, with 
a yearly cost depending on the patient weight but usually representing > 200.000 €/year/patient5. This is also 
commonly associated to undesired immune reactions that minimize the therapeutic effects of the protein drug. 
Moreover, for systemically administered drugs, only a small portion of the active compound is expected to reach 
the target6.
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In this context, there is a growing interest in the development of new materials as controllable systems for 
sustained protein release. Ideally, the resulting hybrid materials (scaffold plus functional protein drug) could be 
immobilized in a given tissue as drug depots for long term local supply of the embedded protein. Then, hydrogels, 
polymers, and other porous materials and biomaterials are being explored as scaffolds for drug inclusion in vitro 
and further slow release in vivo7–16. As in other nanomedical applications, toxicity of the scaffold material is a rele-
vant matter of concern, and the long term stability and interactivity of the scaffold structure itself with body com-
ponents are critical issues. Then, the use of homogenous delivery platforms in which the protein drug itself is also 
the immobilizing scaffold would be highly convenient to skip the use of potentially toxic, xenobiotic carrier plat-
forms. In this context, the endocrine system offers some important lessons about sustained protein release from 
chemically homogenous structures. Many secretory cell types in the human body accumulate functional proteins 
for long-term storage, in the form of compact protein clusters17,18. These act as secretory granules that are formed 
by self-assembling polypeptides with a high extent of internal molecular organization. Such protein reservoirs 
show an amyloidal nature rich in cross-β sheet contacts that provide stable and robust scaffolds to retain protein 
as in vivo depots. As a response to appropriate stimuli, these functional amyloids release monomeric hormone 
molecules in a functional form19–22 in a poorly investigated process probably assisted by molecular chaperones17.
On the other hand, IBs are cross-β sheet rich, functional amyloids formed in recombinant bacteria23 observed 
as mimetics of the above mentioned secretory granules24–26. They combine amyloidal and non-amyloidal protein 
forms in organized sub-micron particles, in which the amyloidal skeleton offer mechanical stability and retains 
active, properly folded protein forms through stereospecific interactions8,24. Any therapeutically valuable protein 
produced in bacteria can be packaged as IBs27, and in addition, bacterial IBs show a high intrinsic and sponta-
neous penetrability into mammalian cells where they deliver, assisted by molecular chaperones, the functional 
protein fraction embedded into the amyloidal scaffold28. Noting the structural and functional analogies between 
secretory granules and IBs, the bacterial products would potentially be ideal homogenous materials for sustained 
protein delivery in vivo through bioinspired therapeutic approaches. In this context, we have explored here the 
potential of IBs formed by a model protein with antitumoral activity, in inducing apoptosis upon prolonged local 
exposition to target tissues.
Results and Discussion
Bacterial IBs are regular shaped soft materials that show a moderate polydispersion in size (Fig. 1)29,30. Their sticky 
nature31 would prevent them from being used in systemic delivery (as aggregation in lungs would be anticipated) 
while it would instead favour their retention in tissues if administered locally by injection. These predictions were 
confirmed by intravenous (iv) tail vein administration of suspended fluorescent IBs formed by VP1TFP (IBVP1TFP) 
(as model fluorescent materials suitable to easy monitoring) in subcutaneous (sc) tumor-bearing mice. The 
ex vivo fluorescent imaging (FLI) at early (a few hours) and long-time (1 day) post administration demonstrated 
that IBVP1TFP got first-pass retained into lung capillaries upon systemic delivery (Fig. 2A), being an indicative 
of aggregation. Moreover, accumulation of IBVP1TFP into tumor, liver, spleen, kidney, stomach, intestine, heart 
and skin tissues were not detected at any of the time points studied (4 and 24 h, data not shown). While these 
data precluded further consideration of IBs as circulating protein drug carrier materials, it was in agreement 
Figure 1. Morphometric analysis of amyloid materials at structural and ultrastructural levels.  
(A) Representative FESEM overviews and details (inboxes) of the amyloidal particulate materials used for 
immobilization, which occurred as rather homogenous populations. Size range of IBVP1TFP was 400–500 nm, 
200–300 nm for IBVP1GFP and 500–600 nm for IBT22-GFP-H6 (n > 200). Size bars are common in all images and 
all inboxes as magnifications are equivalent. (B) Broad field confocal images of the materials and 3D IMARIS 
reconstructions of representative particles (inboxes). Particle sizes here might be largely overestimated due to 
fluorescence emission.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:35765 | DOI: 10.1038/srep35765
with possibilities for retention once locally implanted. Solid tumors are highly vascularized tissues, and a poorly 
stable material would be then easily lost by clearance through the blood stream. In contrast, mechanically stable 
and firmly attached entities should be predicted as long lasting. Thus, to check the potential of the material as 
protein depots, IBVP1TFP were intratumorally injected in mice harboring sc tumors of human colon cancer cells. 
Interestingly, the fluorescent material accumulated in tumor in a dose-dependent way, and the fluorescent light 
emission signal was stable and steadily localized in the first hours post implantation at each corresponding given 
dose in vivo (Fig. 2B). Moreover, ex vivo FLI of tumors 7 days post local IBVP1TFP implantation still showed clusters 
of the material in the local injection site (Fig. 2C), with steady fluorescence intensities along time for the dose of 
12 μ g per mouse. Even, this fluorescence emission was still within the order of magnitude of the light produced 
by IBVP1TFP in vitro (Supplementary Figure 1). Since IBVP1TFP signal was not found in other tissues (data not 
shown) no important fractions of the material appeared to have migrated, at least as major detectable clusters. 
Importantly, no signs of systemic toxicity were observed such as body weight loss or changes in physical appear-
ance or behavioural patterns (data not shown).
These observations, favourable regarding in vivo stability of the material even in irrigated tissues, prompted 
us to explore further the hypothesis of IBs as functional mimetics of secretory granules. For that, we evaluated 
Figure 2. Whole-body biodistribution of fluorescent amyloids upon intravenous or intratumoral 
administration in a HT-29 colorectal cancer model. (A) Ex vivo lung fluorescence imaging (FLI) at 4 and 
24 h post administration of IBVP1TFP protein particles at 60 μ g/mouse by intravenous administration route. 
Ex vivo lung-accumulation of the material was quantified by measuring fluorescent intensity (left plot), while 
representative ex vivo fluorescent images of the excised lungs are shown (right panel). (B) Non-invasive 
monitoring of IBVP1TFP tumor-accumulations a long time after intratumoral administration at 12, 24 and 60 μ g/
mouse of IBVP1TFP. In vivo tumor-accumulation of the material was quantified (left plot), and representative  
in vivo fluorescent image of tumor-accumulation at 24 h post administration are shown (right panel). (C) Ex vivo 
tumor FLI at 4 h after intratumoral administration at 12, 24 and or 60 μ g/mouse, and 7 days after intratumoral 
administration of 12 μ g/mouse of the material. Ex vivo tumor-accumulation of IBVP1TFP was quantified  
(left plot), and representative ex vivo fluorescent images of the excised tumor (whole- and sectioned-tumor) are 
shown (right panel). In all cases, the total tissue-accumulations were quantified by measurements of fluorescent 
intensity expressed in Radiant Efficiency, MEAN ± SEM. Pseudocolor scale bars were consistent for all images 
in order to show relative changes for each corresponding images.
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the availability of the functional IB protein fraction to the cells in the vicinity of the reservoir implantation 
site. T22 is a peptidic ligand and a CXCR4 antagonist that acts extracellularly by competing with SDF-1α for 
binding to this membrane receptor32. High doses of this peptide trigger the inhibition of signal transduction 
downstream of CXCR4 leading to proliferative block, apoptotic induction and tumor growth inhibition in 
CXCR4-overexpressing breast33 and brain34 cancer models. The protein fusion T22-GFP-H6 was produced in 
bacteria in form of fluorescent, T22-containing IBs (IBT22-GFP-H6) for testing the biological effects of the material 
when implanted in CXCR4+ colorectal cancer models. The coincidence in the same macromolecule of T22 as 
effector moiety and of GFP as tracking agent renders an unusually convenient system to analyse cell responses 
with an immediate evidence of protein activity and localization.
Upon injection in sc tumors, local fluorescence of IBT22-GFP-H6 was clearly dose-dependent and largely stable 
along time (Fig. 3A). About 75 % of the initial fluorescence emission was still linked to the material in tumor 3 
days after local injection and decreased only till 40 % in 7 days postinjection (Fig. 4). No toxic side effects were 
detected in the animals as indicated by lack of body weight loss or clinical signs (not shown). Again, no signifi-
cant fluorescence levels were observed in analysed organs other than primary tumor (Fig. 3A). Interestingly, the 
distribution of the IB through the tumor tissue increased with the dose of injected IBs, clearly covering a wider 
area and indicating a significant level of diffusion of the material and a residual circulating fraction, probably in 
soluble form since no lung aggregation was observed (Fig. 3B and Table 1). Fluorescent signals were correlated 
with anti-GFP immunostaining of tumor (Fig. 4B,C) and GFP was detected both in the extracellular matrix and 
inside tumor cells at any of the time points studied: 5 h, 3 and 7 days (Fig. 4C).
When exploring the biological impact of the IB-contained effector T22 on surrounding tissues, we observed 
a dramatic occurrence of apoptotic events in the tumor tissue (Fig. 5A,C), that was not observed for the control, 
closely related T22-devoid IBVP1GFP. The number of apoptotic bodies was unperceived 5 h after injection but they 
Figure 3. Whole-body biodistribution of functional fluorescent amyloids in CXCR4+ colorectal murine 
model. (A) Representative ex vivo fluorescent images of the excised tumor and organs (brain, liver, kidney and 
lung and heart) remaining in tumor tissue at 5 h, and 3 or 7 days post administration of IBT22-GFP-H6 protein 
particles at 60 μ g/mouse or 200 μ g/mouse using the intratumoral route. (B) Fluorescence emitted by soluble 
protein species in plasma, which were released by IBT22-GFP-H6 tumor deposits to the bloodstream at 5 h, and 3 
or 7 days after injection of a 200 μ g/mouse intratumoral dose. Pseudocolor scale bars were consistent among 
images in order to show relative changes when being compared.
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rose at 3 days and 7 days, in parallel with a significant drop in the number of mitotic cells, not observed when 
implanting control, non-functional IBs (Fig. 5B,D). The coincidence of inhibited cell proliferation and apop-
totic induction was indicative of the fusion protein being available to the surrounding tissues in the course of 
prolonged time periods. This apoptotic induction was associated with sustained caspase-3 activation along time 
(Fig. 5E,F).
Around 20 % of the IB protein is organized as proteinase K-resistant amyloid fibers35,36, in a pattern similar 
to that of protein hormones in the human secretory system. Such amyloidal network ensures a stable fibrous 
scaffold that confers mechanical stability and high porosity to IBs enabling them to be used as functional bio-
materials26,37. The remaining IB protein fraction occurs embedded within this network probably by sterospecific 
interactions35,38, as native-like rich protein versions that are releasable upon internalization by mammalian cells39. 
Figure 4. Fluorescent emission by IBT22-GFP-H6 deposits remaining in CXCR4+ colorectal tumors after their 
administration. (A) Total IBT22-GFP-H6 protein deposits were quantified measuring fluorescent intensity at 5h, 3 and 
7 days after intratumoral injection of 200 μ g/mouse. Data were expressed in Radiant Efficiency. (B) Quantitation 
of total IBT22-GFP-H6 protein deposits plus released soluble proteins in tumor tissue calculated as an H-score 
for anti-GFP immunostaining (brown colour) at 5 h, and 3 or 7 days post administration. (C) Representative 
microphotographs of GFP inmunohistochemistry in IBT22-GFP-H6 treated tumors at 5 h, and 3 or 7 days. Note the 
higher intensity of GFP staining in some tumor areas at 5 h and 3 days (black arrows) and the higher dispersion 
of protein distribution observed inside the tumor at day 7 post-injection. Quantitative data were expressed as 
mean ± SE *,**Statistically significant at p < 0.05 or p < 0.01, respectively.
Parameter
Time
0 hours 5 hours 3 days 7 days
IBs in tumor (μ g) 200 184.5 155.3 87.9
IHC GFP H-score N.d 140 ± 5 120 ± 12 89 ± 15
Cleaved-Caspase 3 N.d 3.2 ± 0.3 3.7 ± 0.6 3.5 ± 0.4
Apoptosis N.d 3.7 ± 0.2 5.9 ± 1 8.0 ± 0.2
Mitosis N.d 4.9 ± 0.3 3.9 ± 0.7 3.1 ± 0.1
Plasma (μ g/ml) 0 2.9 16.4 0
Table 1.  Kinetics of IBT22-GFP-H6 protein depots remaining in tumor and soluble species released 
to plasma, and their antitumor effect in tumor tissue. Samples were analyzed at 0 h, 5 h, 3 and 7 days after 
intratumoral injection at a 200 μ g/mouse dose. IHC GFP Score: Immunohistochemical quantitation of proteins 
containing GFP in tumor tissue N.d.: not done.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:35765 | DOI: 10.1038/srep35765
Figure 5. Apoptotic and mitotic index recorded in CXCR4+ tumors. Quantitation of apoptotic figures 
detected by nuclear condensation or nuclear fragmentation after Hoescht staining (A) or mitotic figures  
(B) after Hematoxylin-eosin staining in SP5 tumors at day 7 post intratumoral administration of IBT22-GFP-H6 
protein particles at 60 or 200 μ g/mouse. (C,D) Representative microphotographs of apoptotic figures by 
Hoescht ((C), white arrows ) or HE ((D), white arrows) staining or mitotic figures ((D), black arrows) by HE 
staining after local intratumoral injection of 200 μ g/mouse dose of targeted IBT22-GFP-H6 or non-targeted IBVP1GFP 
(x 400 magnification). (E) Quantitation of the number of positive cells displaying cleaved (active) caspase-3 
immunostaining in tumors at 5 h, and 3 or 7 days after intratumoral administration of 200 IBT22-GFP-H6 compared 
to non-treated tumors. (F) Representative microphotographs of active caspase-3 positive cells (brown stained 
tumor cells; black arrows) at the studied time point. Data expressed as mean ± SE *,**Statistically significant at 
p < 0.05 or p < 0.01, respectively.
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In fact, upon in vitro incubation with physiological buffer, an immediate but time-limited amount of IB protein 
(about 5 %) is released from IBs in the active form40. Such protein loss is probably occurring through an equilib-
rium between soluble and aggregated protein species, with a kinetics controlled by an aggregation/dissociation 
constant. However, the fraction of released functional protein appears to be higher upon internalization into 
mammalian cells, what might be linked to the suggested involvement of cell chaperones in the disintegration of 
exogenous IBs41–44 and not subjected to physicochemical equilibrium constants. To confirm such protein release 
and its time-prolonged nature we determined, by GFP immunostaining, the amount of IB protein still associ-
ated to engulfed IBs and the IB protein fraction free from the bulk material, in the cell cytoplasm. As observed 
(Fig. 6A,B), more than 20% of IB protein is found free in the cell cytoplasm, 24 h after exposure of cultured 
mammalian cells to IBVP1GFP. Interestingly, some IBs show their natural electrodense nature under transmission 
electron microscopy (Fig. 6A, red borders) while others are much loser and less dense (Fig. 6A, yellow borders). 
These images are compatible with those observed upon proteinase K treatment of isolated IBs, in which an impor-
tant fraction of the protein is degraded and the amyloidal skeleton, free from functional protein, remains36. This 
amyloidal network represents about 20 % of the total recombinant protein in IBs, but this percentage, as well 
as the amount of functional protein that can be released from IBs seems to be regulatable by the proper choice 
of the genetic background of the bacteria where IBs are produced36, and by the production conditions, such as 
temperature and others45–47. The potential to obtain IBs with variable amounts of releasable protein and with 
different global conformational status48,49 might offer opportunities for a better control of the protein release 
upon injection, as well as a way to minimize the amount of unfolded protein, what could contribute to undesired 
immune responses.
In addition to the releasable nature of a fraction of IB protein, the high inherent membrane-activity of bac-
terial IBs allows efficient adhesion and cell penetration in absence of cytotoxicity, properties that justified the 
exploration of IBs as both functional topographies in tissue engineering and as protein delivery agents in replace-
ment therapies24. In this context, the absence of intrinsic toxicity of bacterial IBs has been widely demonstrated 
by conventional procedures on IBs formed by diverse proteins with potential biomedical interest, in therapeutic/
prophylactic setting ups. This includes cytoskeleton proteins50, enzymes39, chaperones39 and growth factors42,43,51 
among others, and very recently, cytokines in a Zebrafish animal model52.
Beyond the well-known applications of bacterial IBs as vehicles for functional protein in cell culture and 
oral administration53–56, we demonstrate here that bacterial IBs act as in vivo depots of functional proteins upon 
their immobilization by local injection. The availability for interaction and signalling of a CXCR4 peptide ligand 
that was part of an IB-forming fusion protein and the dramatic impact promoting apoptosis in primary tumor 
fully confirm the successful mimicry of IBs as implantable homogenous materials for sustained protein release. 
The fact that the tissue volume in which IBs occur is dose-dependent and expands with increasing IB amounts 
(Figs 2B,C and 3B,C) opens a possibility to regulate the zone of therapeutic impact, what could be also defined by 
the selection of multiple injection sites, if required.
Finally, the recent identification of IB formation in food-grade bacteria57, the development of endotoxin-free 
E. coli strains58 and their adaptation to the production of endotoxin-free IBs59 further expand the opportunities 
for the in vivo uses of IBs, supporting again the added values of biofabrication versus chemical synthesis in the 
production of functional materials.
Methods
Bacterial production of IBs. VP1TFP is a far-red fluorescent protein TurboFP635 fused to an aggrega-
tion prone viral peptide (from foot-and-mouth disease virus). VP1GFP is an equivalent protein containing the 
enhanced GFP, while T22-GFP-H6 contains T22 instead of VP1. IB versions of these proteins (Fig. 1) were pro-
duced from encoding plasmid vectors by IPTG-mediated induction in E. coli as described39,60,61, purified by a 
stringent protocol designed to minimize molecular contamination from the producing cells62, and strictly tested 
Figure 6. Protein release from IBs. (A) Immunogold labeling of GFP in HeLa cells after 24 h of exposure to 
VP1-GFP-H6 IBs. Blue arrows indicate labeling in the IB particle while red arrows indicates labeling of released 
protein to the cell cytoplasm. Highly electrodense IB particles with standard morphometries are shadowed in 
red while those with loose morphologies and showing lower electrodensity, in yellow. The scale bar represents 
200 nm. (B) Quantification of IB-attached and IB-free immunolabeling signals at this incubation time.
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by the absence of contaminating, full cell bacteria by described procedures62. The absence of toxicity of IBs on 
mammalian cell cultures was regularly determined by conventional MTT assays, resulting in viability values 
always over 90 % (usually over 95 %; not shown). This is coincident with multiple reports showing the lack of 
intrinsic cytotoxicity of IBVP1GFP and IBTF1GFP produced by optimized protocols28,39,61,63. Protein production and IB 
purification has been partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production 
Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN)/ IBB, at the UAB SepBioES 
scientific-technical service.
Field Emission Scanning Electron Microscopy (FESEM). The ultrastructural details of size, shape 
and surface aspect were evaluated at nearly native state with a Field Emission Scanning Electron Microscope 
(FESEM). Purified IBs were diluted in water and microdrops of 10 μ l of each sample were deposited over silicon 
wafers (Ted Pella, Reading, CA, USA) and air dried. Then, the materials were immediately observed without 
coating in a FESEM Zeiss Merlin (Zeiss, Oberkochen, Germany), operating at 2 kV and equipped with a high 
resolution in-lens secondary electron detector.
In vivo experiments. All in vivo experiments were performed by the ICTS “NANBIOSIS”, more specifically 
by the CIBER-BBN’s in vivo Experimental Platform of the Functional Validation & Preclinical Research (FVPR) 
area (http://www.nanbiosis.es/unit/u20-in-vivo-experimental-platform/) and the Nanotoxicology platform of IIB 
Sant Pau (http://www.nanbiosis.es/portfolio/u18-nanotoxicology-unit/. Animal care was handled in accordance 
with the Guide for the Care and Use of Laboratory Animals of the involved institutions and all the in vivo pro-
cedures were approved by the Hospital de Sant Pau and Hospital Vall d’Hebron Animal Ethics Committees and 
performed according to EC directives. Detailed protocols are given in the Supplementary information.
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